文献速递疝与腹壁外科围术期管理与 ERAS

生物补片与合成补片在腹股沟疝修补中的结局比较:系统评价与Meta分析

Comparative outcomes of biologic versus synthetic mesh in inguinal hernia repair: A systematic review and meta-analysis.
PubMed 文献 · Surgery · 2026-06-15

该系统评价与Meta分析纳入6项随机对照试验共1,010例成人腹股沟疝患者,比较生物补片与合成补片在开放或腹腔镜修补后的结局。生物补片组疝复发风险与合成补片无统计学显著差异,但血清肿风险显著升高,术后慢性疼痛评分显著降低,尤其在开放修补后。结论认为生物补片在择期腹股沟疝修补中未显示优于合成补片,且成本明显增加。

要点

  • 生物补片与合成补片的疝复发风险无统计学显著差异(RR 2.45,95%CI 0.90-6.66,P=.08)。
  • 生物补片组血清肿风险显著高于合成补片(RR 1.58,95%CI 1.07-2.34,P=.02)。
  • 生物补片组术后慢性疼痛评分显著更低(SMD -0.37,95%CI -0.63至-0.11,P=.006),尤其在开放修补后。

核心结论

  • 生物补片在择期腹股沟疝修补中未显示优于合成补片,疝复发与手术部位感染无显著差异。
  • 生物补片虽与术后慢性疼痛降低相关,但血清肿发生率更高且成本明显增加。
  • 需更大规模、多中心、设计良好且长期随访的随机对照试验进一步评估。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Web of Science和EBSCO数据库。
  • 纳入比较生物补片与合成补片在成人开放或腹腔镜腹股沟疝修补中的随机对照试验,共6项、1,010例患者。
  • 采用随机效应模型计算风险比和标准化均数差。

主要发现

  • 疝复发:生物补片与合成补片无统计学显著差异(RR 2.45,95%CI 0.90-6.66,P=.08)。
  • 血清肿:生物补片组风险显著更高(RR 1.58,95%CI 1.07-2.34,P=.02)。
  • 手术部位感染与血肿:两组无显著差异。
  • 术后慢性疼痛评分:生物补片组显著更低(SMD -0.37,95%CI -0.63至-0.11,P=.006),尤其在开放修补后。

临床怎么用

  • 择期腹股沟疝修补选择补片时,生物补片未显示降低复发或手术部位感染的优势。
  • 若关注术后慢性疼痛可考虑生物补片,但需权衡血清肿风险及明显增加的成本。
  • 生物补片的现有证据尚不足以支持其作为常规首选,宜结合患者情况和费用个体化决策。

局限性

  • 纳入研究仅6项、共1,010例患者,样本量有限。
  • 原文未报告各试验的随访时长及偏倚风险评估细节。
  • 原文未报告成本数据的具体数值,仅描述为substantially increased cost。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparative effectiveness of biologic versus synthetic mesh in inguinal hernia repair remains uncertain, with existing studies reporting inconsistent findings. We aimed to report a meta-analysis of randomized controlled trials comparing the outcomes of synthetic and biologic mesh in open and laparoscopic inguinal hernia repair. METHODS: A literature search of PubMed, Embase, Web of Science, and EBSCO databases was performed to identify randomized controlled trials comparing biologic and synthetic mesh in adult patients undergoing open or laparoscopic inguinal hernia repair. Postoperative outcomes were assessed using pooled analysis and meta-analysis. Risk ratios and standardized mean differences were calculated using random-effects models. RESULTS: Six randomized controlled trials involving 1,010 patients were included. There was no statistically significant difference in hernia recurrence between biologic and synthetic mesh (risk ratio, 2.45; 95% confidence interval, 0.90-6.66; P = .08). Biologic mesh was associated with a significantly higher risk of seroma formation (risk ratio, 1.58; 95% confidence interval, 1.07-2.34; P = .02), whereas no significant differences were observed in surgical site infection or hematoma. Postoperative chronic pain scores were significantly lower in the biologic mesh group (standardized mean difference, -0.37; 95% confidence interval, -0.63 to -0.11; P = .006), particularly following open repair. CONCLUSION: Biologic mesh did not demonstrate superiority over synthetic mesh in elective inguinal hernia repair, with no significant differences in recurrence or surgical site infection. Although biologic mesh was associated with reduced chronic postoperative pain, it was accompanied by a higher incidence of seroma and substantially increased cost. Further evaluation in large, multicenter, and well-designed randomized controlled trials with long-term follow-up is required.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Liu B, Guo R, Cao X, et al. Comparative outcomes of biologic versus synthetic mesh in inguinal hernia repair: A systematic review and meta-analysis. Surgery. 2026. PMID: 42407333. doi:10.1016/j.surg.2026.110392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。